BDandCo launches semaglutide in Brazil to boost metabolic disease treatment; Becton Dickinson stock climbs

Traders Union
All News
Business & Wealth
Companies
Becton Dickinson jumps 4.67% today

Highlights

BDX sustains a robust bullish trend, trading well above key moving averages across all timeframes after a 4.67% daily surge.
Momentum indicators confirm persistent buying and strong price recovery, but overbought signals increase likelihood of a near-term pullback.
For the coming week, BDX is projected to consolidate between $163 and $172, with an 80% probability of further appreciation and low risk of decline to $154–$155.

The collaboration combines leadership in pharmaceuticals and advanced drug delivery technology. It aims to support a consistent and reliable treatment experience for metabolic disease patients.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish trend confirmed as price exceeds key averages and support zones

BDX is trading at $166.34, well above the MA-20 ($155.05), MA-50 ($150.32), and MA-200 ($150.72), confirming a strong bullish trend across short, medium, and long-term timeframes. The Ichimoku Kijun on D1 stands at $154.12, which is substantially below the current price and therefore serves as immediate support; near-term supports cluster at MA-20 ($155.05) and the Ichimoku Kijun ($154.12), while key support lies at MA-50 ($150.32). The next near-term resistance is at MA-5 ($157.55), but since it is far below the current price, attention should shift toward monitoring for new high formations, as the price is at the upper bound of the recent range.

Momentum signals bullish bias but overbought risk on strong weekly gain

Momentum remains firmly bullish, with D1 MACD in buy mode and AO also confirming upward strength, but ADX at 12.73 on D1 indicates that trend strength is still modest. RSI on D1 reads 67.17, tagging bullish but not yet extreme levels, while Stoch RSI and CCI both signal overbought conditions, suggesting increased risk of a near-term pullback. BBP is firmly positive, indicating buyers dominate intraday flows. In today's session, BDX surged 4.67%, a strong daily move. Over the past week, BDX has gained $9.98 (6.38%) from a prev_week_close of $156.36, pushing the price to the very top of the weekly range and confirming a bullish recovery with weekly volatility standing at 10.52%. The tone this week is clear upward momentum to new highs.

Upward bias favored as buy signals outweigh low pullback risk

For the next week, the projected price range is between $163.10 and $171.70, reflecting the prevailing upward bias while remaining within 5% of the current price for realism and respecting the weekly volatility profile. With three out of four W1 indicators—RSI, MACD, and MA-50—signaling buy, the probability of continued price appreciation is high (more than 80%), while a pullback has a very low probability (less than 20%). The baseline scenario is for BDX to consolidate between $163 and $172. In a bullish scenario, the price could break higher toward the upper $171–$175 zone if strong buying persists. On a bearish break of support, a retreat toward the $154–$155 region (Kijun/MA-20 cluster) could follow, though momentum and trend context make this less likely. This projected range places BDX much closer to its 52-week high ($187.35) than its low ($100.31), underscoring strong recent performance and positive sentiment.

Previously it was reported that Becton Dickinson faced ongoing selling pressure, with analysts expressing caution about the potential for a sustained upside move. In light of current developments, investors should monitor for any meaningful shift above resistance levels, as this could indicate an improvement in sentiment and alter the prevailing sideways outlook.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.